Betegségek, amelyek szerepe kevésbé ismert a kardiovaszkuláris kórképekben, azok rosszabb klinikai prognózisában 1. rész
Absztrakt
A hagyományos kockázati tényezőkkel értékelt kardiovaszkuláris egyéni kockázatokon túlmenően bizonyos betegségek, klinikai állapotok is kedvezőtlenül befolyásolhatják a kockázatot. Némely alapbetegségek a kockázatot növelve akár a kardiovaszkuláris betegségek kiváltó okai is lehetnek, illetve azok rosszabb klinikai prognózisával járhatnak. A közlemény olyan kardiovaszkuláris kockázatot növelő, betegséget kiváltható kórképeket mutat be, amelyek nem szerepelnek a hagyományos kockázati tényezők között: autoimmun-, reumatológiai-, krónikus vese-, obstruktív tüdő-, daganatos-, hematológiai betegségek.
Hivatkozások
Piepoli MF, Hoes AW, Agewall S és mtsai: 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Pre-vention in Clinical Practice (constituted by representatives of 10 societies and by invited experts). Developed with the speci-al contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2016; 37: 2315-2381. https://doi.org/10.1093/eurheartj/ehw106
Visseren FLJ, Mach F, Smulders YM és mtsai: 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice: Developed by the Task Force for cardiovascular dis-ease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies With the special contribution of the European Association of Pre-ventive Cardiology (EAPC). Eur. Heart J 2021; 42: 3227-3237. https://doi.org/10.1093/eurheartj/ehab484
Kunadian V, Chieffo A, Camici PG és mtsai: An EAPCI Expert Consensus Document on Ischaemia with Non-Obstructive Coronary Arteries in Collaboration with European Society of Cardiology Working Group on Coronary
Pathophysiology & Microcirculation Endorsed by Coronary Vasomotor Disorders International Study Group. Eur Heart J 2020; 41: 3504-3520. https://doi.org/10.1093/eurheartj/ehaa503
Pearson TA, Mensah GA, Hong Y és mtsai: CDC/AHA workshop on markers of inflammation and cardiovascular disease: Application to clinical and public health practice: Overview. Circulation 2004; 110: e543-544. Prasad M, Hermann J, Gabriel SE és mtsai: Cardiorheumatology: Cardiac involvement in systemic rheumatic disease. Nat Rev Cardiol 2015; 12: 168-176. https://doi.org/10.1038/nrcardio.2014.206
Zanatta E, Colombo C, D'Amico G és mtsai: Inflammation and Coronary Microvascular Dysfunction in Autoimmune Rheu-matic Diseases. Int J Mol Sci 2019; 20: 5563. https://doi.org/10.3390/ijms20225563
Faccini A, Kaski JC, Camici PG: Coronary microvascular dysfunction in chronic inflammatory rheumatoid diseases. Eur Heart J 2016; 37: 1799-1806. https://doi.org/10.1093/eurheartj/ehw018
Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int 2024; 105: S117-314.
A Belügyminisztérium egészségügyi szakmai irányelve a felnőttkori idült vesebetegség diagnózisáról és kezeléséről. Hypertonia és Nephrologia. 2025; 29(Suppl. 1): 1-48.
Jankowski J, Floege J, Fliser D és mtsai: Cardiovascular disease in chronic kidney disease: pathophysiological insights and therapeutic options. Circulation 2021; 143: 1157-1172. https://doi.org/10.1161/CIRCULATIONAHA.120.050686
Marx-Schütt K, Cherney DZI, Jankowski és mtsai: Cardiovascular disease in chronic kidney disease, European Heart Journal 2025; 46: 2148-2160 https://doi.org/10.1093/eurheartj/ehaf167
Sooltan I, Khan A, Bulugahapitiya S: COPD and CVD: the dangerous duo reshaping cardiopulmonary care. Br J Cardiol 2025; 32: 123-124.
Morgan AD, Zakeri R, Quint JK: Defining the relationship between COPD and CVD: what are the implications for clinical practice? Ther Adv Respir Dis 2018; 12: 1753465817750524. https://doi.org/10.1177/1753465817750524
Maeda T, Dransfield MT: Chronic obstructive pulmonary disease and cardiovascular disease: mechanistic links and implications for practice. Curr Opin Pulm Med 2024; 30: 141-149. https://doi.org/10.1097/MCP.0000000000001040
Finks SW, Rumbak MJ, Self TH: Treating Hypertension in Chronic Obstructive Pulmonary Disease. N Engl J Med 2020; 382: 353-363. https://doi.org/10.1056/NEJMra1805377
Yang YL, Xiang ZJ, Yang JH és mtsai: Association of β-blocker use with survival and pulmonary function in patients with chro-nic obstructive pulmonary and cardiovascular disease: a sys-te-matic review and meta-analysis. Eur Heart J 2020; 41: 4415-4422. https://doi.org/10.1093/eurheartj/ehaa793
Lyon AR, López-Fernández T, Couch LS és mtsai: 2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J 2022; 43: 4229-4361.
Wilcox NS, Amit U, Reibel JB és mtsai: Cardiovascular disease and cancer: shared risk factors and mechanisms. Nat Rev Cardiol. 2024; 21: 617-631. https://doi.org/10.1038/s41569-024-01017-x
Sharma A, Darren C, Tsang DC és mtsai: Prevalence of Cardiovascular Disease and Risk Factors Among Cancer Patients: 5-Year National Inpatient Sample Analysis. JACC: Advances. 2026; 4: 102690. https://doi.org/10.1016/j.jacadv.2026.102690
Newman AAC, Dalman JM, Moore KJ. Cardiovascular Disease and Cancer: A Dangerous Liaison. Arterioscler Thromb Vasc Biol. 2025 Mar; 45(3): 359-371. https://doi.org/10.1161/ATVBAHA.124.319863
van Dorst DCH, Dobbin SJH, Neves KB és mtsai: Hypertension and Prohypertensive Antineoplastic Therapies in Cancer Patients. Circ Res 2021; 128: 1040-1061. https://doi.org/10.1161/CIRCRESAHA.121.318051
Kidoguchi S, Sugano N, Tokudome G és mtsai: New concept of onco-hypertension and future perspectives. Hypertension. 2021; 77: 16-27. https://doi.org/10.1161/HYPERTENSIONAHA.120.16044
Moslehi JJ: Cardiovascular toxic effects of targeted cancer therapies. N Engl J Med 2016; 375: 1457-1467. https://doi.org/10.1056/NEJMra1100265
Yong JH, Mai AS, Matetić A és mtsai: Cardiovascular Risk in Patients with Hematological Malignancies: A Systematic Review and Meta-Analysis. Am J Cardiol 2024; 212: 80-102. https://doi.org/10.1016/j.amjcard.2023.11.039
Tefferi A, Barbui T: Polycytemia vera and essential thrombocythemia: 2019 update on diagnosis risk stratification and management. Am J Hematol 2019; 94133-43. https://doi.org/10.1002/ajh.25303
Rymer JA, Rao SV. Anemia and coronary artery disease: pathophysiology, prognosis, and treatment. Coron Artery Dis 2018; 29: 161-167. https://doi.org/10.1097/MCA.0000000000000598
Lanser L, Fuchs D, Scharnagl H és mtsai: Anemia of Chronic Disease in Patients With Cardiovascular Disease. Front Cardiovasc Med. 2021 Aug 12; 8: 666638. https://doi.org/10.3389/fcvm.2021.666638
Wang H, Huang Z, Du C, Dong M: Iron Dysregulation in Cardiovascular Diseases. Rev Cardiovasc Med. 2024 Jan 10; 25(1): 16. https://doi.org/10.31083/j.rcm2501016
Kotze MJ, van Velden DP, van Rensburg SJ, Erasmus R: Pathogenic Mechanisms Underlying Iron Deficiency and Iron Overload: New Insights for Clinical Application. EJIFCC 2009; 20: 108-123.
Baddam S, Chen RJ: Iron Overload and Toxicity. In: Stat- Pearls [Internet]. Treasure Island (FL): 2026. https://www.ncbi.nlm.nih.gov/books/NBK526131/
Copyright (c) 2026 Szerző
This work is licensed under a Creative Commons Attribution 4.0 International License.
